Biocon Biologics and Civica, Inc. on Thursday announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. According to the company’s ...

Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug ...

safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

Under the terms of the agreement, Biocon Biologics will supply insulin aspart drug substance to Civica, who will use the drug substance to produce insulin aspart drug product, a rapid-acting insulin ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

The current review has used an EBM approach to evaluate the strength and validity of the evidence supporting the clinical efficacy and tolerability and the administration benefits of insulin ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Assuming that rapid-acting insulin analogs last for 5 hours is a safe general rule. Examples include Aspart (Novolog) and Lispro (Humalog). Regular human insulin: The onset of regular human ...